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Mitochondrial Mutations in 
Cholestatic Liver Disease with 
Biliary Atresia
Hong Koh  1, Gun-Seok Park2,4, Sun-Mi Shin2,5, Chang Eon Park2, Seung Kim1, Seok Joo Han3, 
Huy Quang Pham2, Jae-Ho Shin2 & Dong-Woo Lee2
Biliary atresia (BA) results in severe bile blockage and is caused by the absence of extrahepatic ducts. 
Even after successful hepatic portoenterostomy, a considerable number of patients are likely to show 
progressive deterioration in liver function. Recent studies show that mutations in protein-coding 
mitochondrial DNA (mtDNA) genes and/or mitochondrial genes in nuclear DNA (nDNA) are associated 
with hepatocellular dysfunction. This observation led us to investigate whether hepatic dysfunctions in 
BA is genetically associated with mtDNA mutations. We sequenced the mtDNA protein-coding genes 
in 14 liver specimens from 14 patients with BA and 5 liver specimens from 5 patients with choledochal 
cyst using next-generation sequencing. We found 34 common non-synonymous variations in mtDNA 
protein-coding genes in all patients examined. A systematic 3D structural analysis revealed the 
presence of several single nucleotide polymorphism-like mutations in critical regions of complexes I to 
V, that are involved in subunit assembly, proton-pumping activity, and/or supercomplex formation. 
The parameters of chronic hepatic injury and liver dysfunction in BA patients were also significantly 
correlated with the extent of hepatic failure, suggesting that the mtDNA mutations may aggravate 
hepatopathy. Therefore, mitochondrial mutations may underlie the pathological mechanisms 
associated with BA.
Cholestasis is a condition that leads to bile stasis and the accumulation of potentially toxic bile acids in the liver 
and the systemic circulation1. The condition can be caused by inflammation, viral infection, autoimmune dis-
ease, or congenital disorders of the hepatobiliary systems2–4. In particular, biliary atresia (BA) is a progressive 
fibro-inflammatory neonate cholangiopathy that is defined by severe alterations in hepatic morphology and 
physiology5–7. BA is the most common cause of cholestatic liver disease and life-saving liver transplantation in 
children8. Hepatic portoenterostomy (also referred to as the Kasai procedure) is a surgical treatment performed 
on infants with BA to allow for bile drainage. Although not perfectly curative, this procedure may relieve jaundice 
and stop liver fibrosis, allowing normal growth and development to occur9. After surgery, bilirubin levels will 
fall to normal levels in about 50% of infants, allowing 40–50% of affected infants to retain their own liver and to 
reach the age of 5–10 years10. The remaining 50% of affected children will not regain adequate bile flow and liver 
function, and may require a liver transplantation.
Many critical metabolic functions such as gluconeogenesis, triacylglyceride oxidation, fatty acid decompo-
sition, amino acid deamination and transamination, and most plasma protein synthesis are carried out pre-
dominantly in hepatocytes11,12. Thus, hepatocytes are rich in mitochondria, as each cell contains about ~1,000 
mitochondria; ~18% of the entire cell volume. It is clear that impaired mitochondrial function may cause severe 
damage to hepatocytes, thus affecting many vital cellular functions13–15.
Tissue affected by chronic liver disease undergoes persistent and massive apoptosis16. Apoptosis-mediated 
fibrogenesis seems to be tightly associated with alterations in mitochondrial function17. Mitochondria play an 
essential role in the production of adenosine triphosphate (ATP) that is used as a cellular energy currency and 
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reactive oxygen species (ROS) that are involved in signaling, pumping of cytosolic Ca2+, and the regulation of 
apoptosis18. Mutations in mitochondrial DNA (mtDNA) can alter the efficiency of cellular energy transduction, 
resulting in mitochondrial dysfunction19,20. Multisystemic disorder results in several distinct syndromes such 
as the Reye’s syndrome21, Wilson’s disease22, exercise intolerance23, and Zellweger syndrome24. Likewise, liver 
cirrhosis appears to be associated with hepatocytic mitochondrial dysfunction25. It remains unclear whether such 
dysfunctional hepatic mitochondria are transmitted by nonmendelian inheritance, maternal inheritance, or a 
sporadic condition. Until recently, little is known about the molecular basis of BA, as the sole manifestation of 
mitochondrial dysfunction in this disease was in sporadic cases. However, several reports regarding biliary atresia 
splenic malformation syndrome26, cystic BA27, and cytomegalovirus-IgM(+) associated BA28 would suggest that 
there is a root cause in mitochondrial dysfunction.
Human mtDNA is found in the mitochondrial matrix and consists of 13 structural genes that encode inte-
gral membrane subunits for complexes I, III, IV, and V in the mitochondrial respiratory chain29 (Fig. 1). The 
mitochondrial matrix possesses an incomplete mtDNA repair system, and is highly sensitive to ROS-induced 
oxidative damage because of its proximity to the inner mitochondrial membrane where most ROS are pro-
duced30–32. Accumulation of toxic bile acids in the liver, oxidative stress, and systemic circulation negatively affect 
the mitochondrial function by directly impairing liver respiratory chain activity33,34. In addition, non-functional 
mitochondria are important for the production of ROS, that in turn can promote the onset of apoptosis and are 
responsible for the activation of profibrogenic mechanisms35,36. Major alterations to energy metabolism in experi-
mental cholestasis resemble metabolic alterations that are observed in patients with cirrhosis37. Part of the adverse 
effects of bile acids on mitochondrial bioenergetics could be related to disturbances of mitochondrial membrane 
composition33. Yet, the specific mechanisms involved in the onset and development of human hepatic mitochon-
drial dysfunction in liver cholestasis remains unclear.
In this study, using a next-generation sequencing technique, we performed a mitochondrial genome-wide 
analysis to investigate the extent of mtDNA mutations in the liver of 14 BA patients and compare it to that in 
livers from five choledochal cyst (CC) patients as a control. We particularly focused on the genes encoding 
energy-transducing components of the respiratory chain. A comparison of clinical, morphologic, biochemical, 
and genetic features of these patients reveals a remarkable uniformity, suggesting that the mutations in mtDNA 
protein-coding genes are highly associated with BA without evidence of maternal inheritance.
Results
Histological and Biochemical Characteristics of Cholestatic Patients. The clinical characteristics of 
19 patients with chronic liver diseases with BA or CC are summarized in Table 1. Between both groups of choles-
tatic patients, there were distinct characteristics in the parameters of hepatic injury and liver functions. At the 
time of liver wedge biopsy during surgery, BA patients were relatively 1 year older than CC patients. In addition, 
their parameters of hepatic injury and liver function such as aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), AST to Platelet ratio index (APRI), direct bilirubin (D.Bil), gamma-glutamyl transpeptidse 
(γ-GT), and prothrombine time-international normalized ratio (PT-INR) were statistically significantly higher 
than those of CC patients (P value < 0.05). These observations indicated that BA patients exhibited more severe 
damage in liver function than CC patients.
To investigate the state of the patients’ livers in detail, we performed liver function tests for all 19 patients 
with BA or CC (Table 2). All 14 BA patients showed cholestasis with elevated levels of D.Bil and γ-GT together 
with high levels of AST and ALT that are indicative of hepatic injury. APRI, a non-invasive serologic parame-
ter of hepatic fibrosis, was significantly elevated in ten BA patients (patients 7, 8, 9, 11, 12, 13, 14, 16, 17, and 
19). However, we did not find any significant necro-inflammantory changes in histological evaluation. Four of 
the five CC patients displayed only elevated AST levels, while other clinical characteristics were in the normal 
range. In these CC patients, liver injury was not significantly correlated with platelet count, protein level, albumin 
level, and total bilirubin (T.Bil) level. This indicates that CC patients exhibited relatively normal liver function 
and hepatic structure. Thus, hepatic fibrosis in CC patients did not seem to be directly related to liver mito-
chondrial dysfunction, whereas BA patients showed severe hepatic damage with high levels of AST and ALT. 
In particular, histological evaluation demonstrated that nine BA patients (patients 8, 9, 12, 13, 14, 16, 17, 18, 
and 19) exhibited severe destruction of normal hepatic structure (METAVIR ≥ 3), including hepatic fibrosis and 
cirrhosis. However, none of the CC patients presented significant hepatic fibrosis, and all displayed a normal 
hepatic structure (METAVIR = 0). Based on METAVIR and APRI values, significant histological and clinical 
hepatic fibrosis were observed in eight BA patients (patients 8, 9, 12, 13, 14, 16, 17, and 19). Values for albumin 
and PT-INR were relatively decreased in four of the eight BA patients (patients 9, 12, 14, and 17), indicating that, 
in these patients, hepatic synthesis was dysfunctional. However, the other BA patients (patients 8, 13, 16, and 19) 
appeared to retain hepatic biosynthetic function relatively higher than the former patients (patients 9, 12, 14, and 
17) described above. Therefore, our histological and biochemical examination clearly indicated that both CC and 
BA patients showed liver injury. However, in the case of BA patients, the degree of liver function was different 
between patients.
Comparison of total DNA extracted by direct sequencing and mtDNA amplicon sequenc-
ing. To compare the copy numbers of mtDNAs between the BA and CC patients, we calculated the relative 
copy number (Rc) = 2 ΔCt (Ctβ-actin − CtmtDNA). As shown in Fig. 1a, BA patients exhibited a slightly lower mtDNA 
copy numbers than CC patients. Next, in order to examine whether conventional PCR-based amplicon sequenc-
ing provides additional nucleotide variation in hepatic mtDNAs due to PCR bias, we performed direct and ampli-
con sequencing with the same patient samples. For this, we chose three BA patients (Patients 12, 17, and 18) out 
of 14 BA patients. These three patients exhibited different clinical features with respect to the extent of liver injury 
and liver function as described above (Tables 1 and 2). For direct sequencing, we isolated mitochondria from liver 
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tissues, extracted total DNA, and constructed a sequencing library. In the case of amplicon sequencing, mtDNA 
was amplified by PCR using four pairs of overlapping primers, yielding 3,580 bp, 5,548 bp, 4,447 bp, and 5,591 bp 
DNA fragments (Fig. 1b and c). The amplified PCR products were also used to prepare the mtDNA sequencing 
library. An Ion Xpress Barcode Adapter was used to separate sequence data belonging to individual patients for 
both direct sequencing libraries and mtDNA amplicon sequencing prior to emulsion PCR. Both libraries were 
then subjected to the Ion Torrent Personal Genome Machine (PGM) sequencer system. As described in Table 3, 
Figure 1. Schematic representation of the human mitochondrial DNA and the mitochondrial respiratory 
chain. (a) Comparison of the mtDNA copy number in plasma between BA and CC patients. The mtDNA 
copy numbers of CC patient group were slightly higher than those of BA patient group. Data represent the 
mean ± SE. ∗p < 0.05 versus BA. (b) The map of the human mitochondrial genome (NC_012920.1) with the 
protein-coding genes colored according to the complexes to which they contribute subunits, two ribosomal 
RNAs, 22 tRNAs and non-coding D-loop in white. Montage depicting the structural information currently 
available for the five complexes that together contribute to the mitocondrial oxidative phosphorylation 
machinery. (c) Electrophoresis of the amplified DNA fragments for mtDNA by PCR. M, λ/HindIII DNA 
marker; lane 1, PCR product 1 (3,580 bp); lane 2, PCR product 2 (5,548 bp); lane 3, PCR product 3 (4,447 bp); 
lane 4, PCR product 4 (5,591 bp). (d) The mammalian mitochondrial electron transport chain includes the 
proton-pumping enzymes complex I (NADH–ubiquinone oxidoreductase), complex III (cytochrome bc1) and 
complex IV (cytochrome c oxidase), that combined, generate proton motive force that in turn drives F1FO-
ATP synthase. Each complex is embedded in the lipid bilayer with the mitocondrial-encoded subunits colored 
corresponding to the genome diagram. The structure of each respiratory complex is presented: complex I from 
Thermus thermophilus (protein databank (PDB) code 4HEA), complex II from porcine Sus scrofa (PDB 4YXD), 
complex III from bovine Bos taurus (PDB 1L0L), complex IV from bovine B. taurus (PDB 1OCC) and complex 
V from bovine B. taurus (PDB 5ARA). The iron-sulfur cofactors of complex I are depicted as orange and yellow 
spheres. IMS, intermembrane space.
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our results showed a relatively low coverage (<50×) with a <1% mapped mtDNA read percentage, mainly due to 
cross-contamination with nuclear DNA (nDNA) as expected. On the other hand, mtDNA amplicon sequencing 
exhibited a high coverage (>2,000×) with a >92% mapped mtDNA read percentage. The vastly different metrics 
generated by the two sequencing approaches did not give any discrepant or biased results between them, indicat-
ing that mtDNA amplicon sequencing could provide similar results to direct sequencing with respect to the total 
number of identified single nucleotide variations (SNV). Indeed, we found almost the same number and loca-
tion of SNVs for Patient 12 from the direct sequencing and mtDNA amplicon sequencing results. Remarkably, 
mtDNA amplicon sequencing found a 14766 C > T variation in Patient 17, and 16183 A > C and 16189 T > C 
variations in Patient 18, that were not detected by direct sequencing because of insufficient mapped reads ascribed 
to its low average coverage (<40×) (Table 3 and Table S2). On the other hand, a 2156 A insertion in Patient 12, a 
Total BA CC
P(N = 19) (N = 14) (N = 5)
Male (%) 8 (42.1) 7 (50.0) 1 (20.0)
Age (weeks) 15.88 ± 16.80 19.18 ± 17.73 6.67 ± 10.21 0.033
AST (13.0~34.0 IU/L)* 695.2 ± 2095.5 925.1 ± 2421.4 51.4 ± 21.9 0.002
ALT (5.0~46.0 IU/L) 295.7 ± 620.1 396.0 ± 700.9 15.0 ± 9.4 0.003
T.Bil (0.2~0.8 mg/dL) 8.07 ± 2.73 8.35 ± 1.82 7.28 ± 4.66 NS
D.Bil (0.1~0.4 mg/dL) 4.97 ± 3.06 6.50 ± 1.85 0.70 ± 0.35 0.001
Protein (6.0~8.0 g/dL) 5.75 ± 0.63 5.65 ± 0.70 5.60 ± 0.31 NS
Albumin (3.3~5.3 g/dL) 3.68 ± 0.49 3.66 ± 0.54 3.76 ± 0.36 NS
γ-GT (12.0~54.0 IU/L) 578.7 ± 779.7 733.4 ± 860.4 145.8 ± 109.0 0.006
Platelet (150.0~400 103/μL) 354.4 ± 124.4 353.6 ± 133.5 356.8 ± 108.3 NS
PT-INR (0.91~1.16) 1.07 ± 0.31 1.10 ± 0.35 0.98 ± 0.06 0.002
APRI 13.213 ± 48.676 17.771 ± 56.529 0.454 ± 0.245 0.002
METAVIR stage, 0/1/2/3/4 5/0/5/8/1 0/0/5/8/1 5/0/0/0/0
Table 1. Comparison of clinical and biochemical characteristics of all liver diseases between BA and CC 
patients. All data show mean ± SD. AST = aspartate aminotransferase; ALT = alanine aminotransferase; 
T.Bil = total value bilirubin; D.Bil = direct bilirubin; γ-GT = gamma-glutamyl transpeptidase; PT-
INR = prothrombine time-international normalized ratio; APRI = AST to platelet ratio index; BA = biliary 
atresia; CC = choledochal cysts.
Patients Sex Age (wks) Dx METAVIR AST ALT Platelet APRI T.Bil D.Bil Pro Alb γ-GT PT-INR
1 F 24.9 CC 0 66 31 309 0.628 0.3 0.2 6.0 4.3 24 1.05
2 M 2.9 CC 0 21 9 298 0.207 12.7 1.2 5.6 3.9 307 0.96
3 F 1.9 CC 0 48 12 331 0.427 9.5 0.7 5.3 3.7 73 0.9
4 F 1.9 CC 0 44 8 549 0.236 5.6 0.7 5.3 3.4 142 1.01
5 F 1.7 CC 0 78 15 297 0.772 8.3 0.7 5.8 3.5 183 0.97
6 M 14.9 BA 2 146 162 351 1.223 7.6 6.2 5.6 3.8 307 0.92
7 M 9.0 BA 2 202 98 275 2.160 11.1 9.1 5.4 3.4 382 0.94
8 M 15.4 BA 3 467 362 427 3.217 11.5 9.5 6.3 4.4 406 0.98
9 F 15.3 BA 3 330 244 505 1.922 9.6 7.5 5.2 3.1 644 1.34
10 F 3.9 BA 2 71 11 276 0.757 7.1 4 4.9 3.3 237 0.97
11 M 9.6 BA 2 174 114 379 1.350 6.1 4.9 5.4 3.8 422 0.98
12 F 10.1 BA 3 148 130 197 2.0879 9 7.6 5.0 2.9 1145 1.19
13 M 61.0 BA 3 206 443 391 1.550 4.6 4 7.1 4.2 3371 1.03
14 M 11.3 BA 3 814 134 207 11.566 8.2 6.6 4.5 3.2 475 1.16
15 F 8.6 BA 2 155 179 545 0.837 8.3 6.7 5.6 4 246 0.99
16 F 17.9 BA 3 227 233 463 1.442 8.4 7.1 6.6 4.5 1658 0.85
17 F 58.7 BA 4 9310 2790 128 213.925 8.1 3.5 5.8 3 180 2.23
18 M 12.9 BA 3 184 193 542 0.999 7.6 6.4 6.2 4.2 541 0.81
19 F 19.9 BA 3 517 451 264 5.760 9.7 7.9 5.5 3.4 253 0.99
Table 2. The histological and clinical characteristics of all patients with cholangiopathy. Age (wks) = age at the 
time of liver wedge biopsy (weeks); Dx = Diagnosis; AST = aspartate aminotransferase (IU/L); ALT = alanine 
aminotransferase (IU/L); APRI = AST to platelet ratio index; T.Bil = total bilirubin (mg/dL); D.Bil = direct 
bilirubin (mg/dL); Pro = Protein (g/dL); Alb = Albumin (g/dL); γ-GT = gamma-glutamyl transpeptidase 
(IU/L); PT-INR = prothrombine time-international normalized ratio.
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523–524 deletion and a 2156 insertion A in Patient 17, and a 281–8289 deletion in Patient 18 were not detected by 
amplicon sequencing mostly because of device-specific indel errors (Table 3 and Table S1). Overall, these results 
indicate that mtDNA amplicon library sequencing is a more efficient approach than direct sequencing to verify 
the mtDNA sequences of liver tissues.
Molecular Genetic Analysis for Cholestatic Patients. To rapidly detect SNVs, mtDNA amplicon 
libraries derived from mtDNAs for 19 cholestatic patients were constructed. We obtained a total of 4,734,991 
raw reads for all 19 samples with an average coverage of >1,000× (Table S2). From 19 sets of mtDNA sequences, 
678 SNVs were identified. Out of these SNVs, 151 non-synonymous variations were found in the 13 mitochon-
drial protein coding sequences. As described in Table 4 and Table S3, the CYB region had the highest number of 
non-synonymous SNVs (41 SNVs), followed by 39 SNVs in ATP6, 17 SNVs in DN4, 16 SNVs in ND2, 10 SNVs 
in ND3, 7 SNVs in COX2, 6 SNVs in ATP8, 6 SNVs in ND1, 5 SNVs in ND5, 3 SNVs in COX1, and one SNV in 
COX3, respectively. SNVs were not identified in ND4L and ND6. Remarkably, novel SNVs in BA patients were 
identified in COX2 (L179 [X, stop]) in six samples (patients 6, 7, 11, 12, 17, and 18), ATP8 (M42X) in one sample 
(patient 1), ND2 (T119A) in 4 samples (patients 9, 12, 14, and 17), and ND4 (S97X) in eight samples (patients 1, 
5, 8, 13, 14, 15, 16, and 19) in the study. Novel SNVs had relatively low frequency (35.64~69.32%) when compared 
with the frequency of other SNVs (Table S3). All samples, except the reference human mitochondrion genome 
(http://www.ncbi.nlm.nih.gov/nuccore/251831106), showed a haplogroup that originated in Asia (Table S2).
Structural Analysis of mtDNA Mutations in Respiratory chains. We aimed to understand the poten-
tial effect of mtDNA mutations on the functionality of the respiratory chain. For this, we investigated whether 
the mutational sites of mtDNA protein-coding genes were structurally associated with their assembly factors, 
causing mitochondrial dysfunction. We constructed 3D model structures of human mitochondrial complexes 
based on the most homologous protein structures available (i.e., Thermus aquaticus thermophilus for complex I 
and Bos taurus for complexes III, IV, and V) using the SWISS-MODEL program (Figs 1d and 2). Additionally, we 
analyzed the predictive effects of mutations on the structure and function of respiratory chain complexes using 
SIFT (http://sift.jcvi.org), PROVEAN (http://provean.jcvi.org), and Polyphen-2 (http://genetics.bwh.harvard.
edu/pph/) web servers (Table 5). These amino acid substitutions (AAS) algorithms were combined to inves-
tigate the effect of mutation on the biological functions of proteins, with an improved prediction accuracy of 
>69% when analyzed with SNPs known to be associated with mitochondrial diseases38,39. Notably, 34 frequent 
non-synonymous variations found in mtDNA protein-coding genes for both BA and CC patients were not identi-
cal to SNPs known for any disease-associations reported in the MITOMAP database. Subsequently, the mutations 
found in this study were mapped onto their human model structures (Figs 2 and S1 to S11).
Out of 45 different polypeptide subunits in human complex I, seven ND subunits that are encoded by mtDNA 
play an important role in the correct assembly of complex I and the ability to reduce oxygen with formation of 
superoxide anion40. Moreover, they are also critical for supercomplex formation of OXPHOS system41. As shown 
in Fig. 2, several mutations found in ND 1 through ND5 subunits, except ND4L and ND6 subunits, occur in 
critical locations near the single electron escaping sites such as FMN, Fe-S clusters and ubisemiquinone bind-
ing site and intersubunit-contact regions. In particular, T275A (ND1), L237M (ND2), T119A (ND2), T114A 
(ND3), Y95H (ND4), and T8A (ND5) seem to be critical presumably because these mutations are located in the 
intersubunit-contact regions (i.e., ND3-ND4L42 and ND4-ND543) for the activity and assembly of whole complex 
I. Among them, T119A and Y95H were assigned as deleterious by AAS prediction (Table 5). In addition, trun-
cation by S97X mutation in ND4 seems to severely affect the correct assembly of complex I. In addition, L237M 
(ND2) and I278V (ND2) may cause the electron leak because these sites are proximal to the N2 cluster of the 
neighboring NuoB (NQO6/PSST) subunit44.
In case of cytochrome b in complex III, I115T and T194A are located near the heme bL site responsible for 
quinone/semiquinone reduction. I78T is also proximal to the heme bH site for quinol oxidation. Thus, these muta-
tions may reduce the electron transferring activity of complex III including proton translocation. However, these 
mutations were not assigned as deleterious based on our AAS models.
For complex IV, M117T and V128I near the nuclear Cu center and di-hemes may hinder the reduction of 
oxygen to H2O. Since COX2 is centered between COX1 and COX3 subunits to assemble the transmembrane 
Sample
12 17 18
Total DNA 
extract
mtDNA 
amplicon
Total DNA 
extract
mtDNA 
amplicon
Total DNA 
extract
mtDNA 
amplicon
Total reference 
length (bp) 16,569 16,569 16,569 16,569 16,569 16,569
Total read count 521,196 226,135 499,861 314,756 511,511 251,829
Mapped mtDNA 
read count 4,899 210,745 2,482 293,863 3,093 232,972
Mapped read 
percentage (%) 0.94 93.19 0.50 99.36 0.60 92.51
Average coverage 42× 2,034× 22× 2,705× 26× 2,164×
SNV row count 33 32 33 32 25 26
Table 3. Sequencing metrics of total DNA extract and mtDNA amplicon. Runs of all three patients’ samples 
were performed independently in triplicates. mtDNA = mitochondrial DNA; SNV = single nucleotide variation.
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subunits, impaired COX2 subunit caused by a L179X mutation is deleterious to the correct assembly of complex 
IV, which was supported by our AAS prediction analyses. Subunits ATP6 (or subunit a) and ATP8 (or A6L) func-
tioning as stators contribute to the stabilization of holocomplex V and to monomer-monomer interactions in 
mammalian mitochondria45,46. Notably, there are six mutations found in ATP6 where rotation is generated by the 
translocation of protons through the interface between the C8-ring and ATP6. Based on the fact that the γ, δ, and 
e subunits in the F1 catalytic domain are bound to the C8-ring, and together these subunits constitute the rotor47, 
it is likely that these mutations affect the catalytic activity of complex V presumably because of perturbation of 
correct assembly. However, no mutation was found in subunit ATP8 (A6L) that helps to keep subunit ATP6 in 
contact with the rotating C8-ring.
Overall, we found 34 SNVs in CC and BA patient mtDNA. Several mutations seem to be critical for mito-
chondrial functionality, as the corresponding residues are located in the critical region of correct assembly and/
or intersubunit contacting region for biological function of the respiratory chain (Fig. 2). Together with AAS 
model-based bioinformatic analyses and clinical features, we assessed the potential impact of these mutations on 
mitochondrial dysfunction in cholangiopathic patients (Table 5). We concluded that some mutations found in 
this study might be associated with mitochondrial dysfunction, presumably underlying the pathogenicity of novel 
mutation in mtDNA protein-coding genes specific for cholestasis.
Patient
Locus
Complex I Complex III Complex IV Complex V
Type No. ND1 ND2 ND3 ND4 ND5 Cyt b COX1 COX2 COX3 ATP6 ATP8
CC
1 L237M(C5178A) T114A(A10398G, C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
I78T(T14949C)/
T194A(A15326G)
T59A(A8701G)/
T112A(A8860G)
L17F(C8414T)/ 
M42X(T8473del)
2 T8A (A12358G)
T7I(C14766T)/
I115T(T15090C)/
T194A(A15326G)
T112A(A8860G)
3 T275A*(A4129G) T8A (A12358G)
T7I(C14766T)/
T194A(A15326G) T112A(A8860G)
4 T122A(A4833G) T114A(A10398G, C10400T)
T7I(C14766T)/
T194A(A15326G)
T59A(A8701G)/
T112A(A8860G)
5 L237M(C5178A) T114A(A10398G, C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G) V128I(G6285A)
T59A(A8701G)/
T112A(A8860G) L17F(C8414T)
BA
6
L237M 
(C5178A)/I278V 
(A5301G)
T114A(A10398G, 
C10400T)
T7I(C14766T)/
T194A(A15326G) M117T(T6253C) L179X(T8119del)
T59A(A8701G)/
T112A(A8860G)
7 L237M(C5178A)/I278V(A5301G)
T114A(A10398G, 
C10400T) I423V(A12026G)
T7I(C14766T)/
T194A(A15326G) L179X(T8119del)
T59A(A8701G)/
T112A(A8860G)
8 V113A(T3644C) L237M(C5178A) T114A(A10398G, C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G)
T59A(A8701G)/
T112A(A8860G) L17F(C8414T)
9 T119A(A4824G) F182L (T12880C)
T7I(C14766T)/
T194A(A15326G)
T13A(A8563G)/
H90Y(C8794T)/
T112A(A8860G)
10 L237M(C5178A) T114A(A10398G, C10400T)
T449A 
(A13681G)
T7I(C14766T)/
T194A(A15326G)
T59A(A8701G)/
T112A(A8860G) L17F(C8414T)
11 T7I(C14766T)/T194A(A15326G) L179X(T8119del)
T112A(A8860G)/
V142I(G8950A)
12 T119A(A4824G)
M4T(T14757C)/
T7I(C14766T)/
T194A(A15326G)
V338M(G6914A) L179X(T8119del)
T13A(A8563G)/
H90Y(C8794T)/
T112A(A8860G)
13 T153M(C3764T) L237M(C5178A) T114A(A10398G, C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G)
T59A(A8701G)/
T112A(A8860G) L17F(C8414T)
14 T119A(A4824G) Y95H(T11042C)/S97X(T11048del)
T7I(C14766T)/
T194A(A15326G)
H90Y(C8794T)/
T112A(A8860G)
15 T114A(A10398G, C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G)
A20T/
T59A(A8701G)/
T112A(A8860G)
16 Y43C(A3434G)/A64V(C3497T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G) T112A(A8860G)
17 T119A(A4824G) F182L (T12880C) T7I(C14766T) L179X(T8119del)
T13A(A8563G)/
H90Y(C8794T)/
T112A(A8860G)
18 A64V(C3497T) T7I(C14766T)/T194A(A15326G)
T63A(A7772G)/ 
L179X(T8119del) T112A(A8860G)
19
L237M 
(C5178A)/
I278V(A5301G)
T114A(A10398G, 
C10400T)
Y95H(T11042C)/
S97X(T11048del)
T7I(C14766T)/
T194A(A15326G)
V248I 
(G9948A)
T59A(A8701G)/
T112A(A8860G)/
A207T(G9145A)
Table 4. Non-synonymous variations in mtDNA encoding regions. *Human residue (Nucleotide) Runs of all 
19 patients‘ samples were performed independently in triplicates.
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Discussion
Patients with chronic liver diseases caused by BA, which is an important cause of liver failure at infancy and 
childhood, undergo progressive hepatological deterioration48. BA is still the most common cause of liver trans-
plantation in children, even after successful Kasai operation. Cholestasis after surgery can lead to the end-stage 
liver disease, caused by mitochondrial damage in hepatocytes. Until now, the pathophysiology of the condi-
tion was unknown. However, it is known that most chronic liver diseases have defects of mitochondrial energy 
production, such as deficiency of an enzyme of the mitochondrial respiratory chain complex20,24. For example, 
recent studies show that mutations in protein-coding mtDNA genes and/or mitochondrial genes in nDNA are 
associated with hepatocellular dysfunction49–51. Therefore, the coding region of mtDNA in hepatocytes may play 
a role in the generation of cholestasis. However, no studies have previously thoroughly reported on the combined 
hepatopathic effects of variants in the hepatic mtDNA. Indeed, abnormal mitochondrial function was present 
in a cirrhosis cohort comprising 45 patients with liver failure50. In addition, Zeharia and coworkers reported 
that two patients suffered from a lethal infantile neurodegenerative disorder accompanied by hepatocellular dys-
function52. Based on increased plasma lactate and alanine levels, and an abnormal urinary organic acid profile 
with 3-methylglutaconic aciduria and excessive excretion of Krebs cycle metabolites, mitochondrial respiratory 
chain defect was suspected. This observation was supported by decreased activity in the mitochondrial respira-
tory chain complexes I, III, and IV in the patients’ livers using exom analysis. In addition, an established mouse 
model demonstrated that the distinct metabolic alterations in mice with a mitochondrial polymorphism associ-
ated hepatic mitochondrial dysfunction was linked to a non-synonymous gene variation (nt7778 G/T) of ATP853.
BA hepatopathy usually appears because of mutations in one or more of the 11 genes encoding subunits of 
complexes I, III, IV, and V (Table 4). In this study, we determined the sequences of the protein-coding mtDNA 
genes in 14 subjects with BA and in five control subjects with CC. In both CC and BA patients, three mutations 
in mtDNA were found dominantly in ATPase 6 of complex V (i.e., T112A) and cytochrome b of complex III 
(T7I, and T194A), which suggests that these mutations are highly associated with liver dysfunction. Additional 
Figure 2. Location of putative mitochondrial mutation sites associated with BA cholestasis in complexes I to V. 
Close-up views of the ND subunits of complex I (a), Cyt b of complex III (b), three Cox monomers of complex 
IV (c), and ATP6 of complex V (d). Thirty-four individual mutation sites are mapped onto their corresponding 
3D model structures depicted as transparent ribbon representation. The side chain of each mutation site 
is shown as a sphere colored by atom type (oxygen in red and nitrogen in blue, respectively) with the 
mitochondrial-encoded subunits. The heme cofactors of Cyt b and COX2 subunits are depicted as yellow stick 
representations, and Cu and Zn cofactors of COX2 depicted as spheres colored in cyan and pink, respectively. 
More detailed locations of mutation sites can be found in Figures S1 to S11.
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frequent mutations (L237M, T114A, and L17F) were also found in ND2 and ND3 of complex I and ATP8 of com-
plex V, respectively. All 14 BA patients had hepatitis that began at infancy and worsened progressively (Table 1). 
For reasons that are not clear, mitochondrial proliferation is not prominent in these two patient groups.
Consequently, NGS-based genomic studies showed that mutations in complex I in 12 BA patients, although all 
14 BA patients exhibit genetic heterogeneity in this condition. Furthermore, all 8 patients who have the of muta-
tion of mtDNA in ND2 and ND4 of complex I showed more severe hepatic dysfunction such as METAVIR, APRI, 
AST, ALT, and PT-INR rather than other BA and CC patients (Table 1). Notably, four (i.e., 9, 12, 14, and 17) of the 
14 BA patients displayed distinct pathogenic mutations (T119A and I278V) in another mtDNA protein-coding 
gene, ND2. Indeed, hepatic malfunction and liver impairment were severely present in all four of these patients 
(Table 2). Another set of mutations in ND4 of complex I (i.e., Y95H and S97X) was found in four (i.e., 8, 13, 16, 
and 19) BA patients. Those patients’ livers were severely fibroticly (fibrotic-Ly) damaged, with relatively pre-
served hepatic functionality. Liver biopsies of these patients showed septal fibrosis, cholestasis, portal and lobular 
Human 
subunit 
(Gene)
Human 
residue 
(Nucleotide)
Predictions
SIFT 
Score* Prediction
PROVEAN 
Score§
Prediction 
(Cutoff = −2.5) Polyphen Score£ Prediction
ND1
Y43C 0.02 affected −6.159 deleterious 0.004 (sensitivity: 0.97; specificity: 0.59) benign
A64V 0.51 tolerated −1.405 neutral 0.002 (0.99; 0.30) benign
V113A 0.00 affected −3.333 deleterious 0.052 (0.94; 0.83) benign
T153M 0.12 tolerated 0.284 neutral 0.458 (0.89; 0.90) damaging
T275A 1.00 tolerated 2.989 neutral 0.001 (0.99; 0.15) benign
ND2
T119A 0.16 tolerated −4.241 deleterious 0.771 (0.85; 0.92) damaging
T122A 0.01 deleterious −0.955 neutral 0.665 (0.86; 0.91) damaging
L237M 0.35 tolerated 0.391 neutral 0.992 (0.70; 0.97) damaging
I278V 0.29 tolerated −0.513 neutral 0.005 (0.97; 0.74) benign
ND3 T114A 0.66 tolerated −1.393 neutral 0.000 (1.00; 0.00) benign
ND4
Y95H 0.00 deleterious −3.729 deleterious 0.999 (0.14; 0.99) damaging
S97X −9.238 deleterious
ND5
T8A 0.38 tolerated −1.344 neutral (score is not available) unknown
F182L 1.00 tolerated −4.330 deleterious 0.993 (0.70; 0.97) damaging
T449A 0.52 tolerated −0.253 neutral 0.006 (0.97; 0.75) benign
Cyt b
M4T 0.11 tolerated −1.128 neutral 0.000 (1.00; 0.00) benign
T7I 0.01 deleterious −2.354 neutral 0.001 (0.99; 0.15) benign
I78T 0.02 deleterious −2.500 deleterious 0.661 (0.86; 0.91) damaging
T194A 0.35 tolerated 0.312 neutral 0.000 (1.00; 0.00) benign
COX1
M117T 0.21 tolerated −2.077 neutral 0.000 (1.00; 0.00) benign
V128I 0.16 tolerated −0.464 neutral 0.240 (0.91; 0.88) benign
V338M 1.00 tolerated 1.043 neutral 0.000 (1.00; 0.00) benign
COX2
T63A 0.07 tolerated −2.121 neutral 0.017 (0.95; 0.80) benign
L179X −13.674 deleterious
COX3 V248I 0.12 tolerated −0.842 neutral 0.000 (1.00; 0.00) benign
ATP6
T13A 0.22 tolerated −2.726 deleterious 0.994 (0.69; 0.97) damaging
A20T 0.21 tolerated −0.404 neutral 0.004 (0.97; 0.59) benign
T59A 0.66 tolerated −0.935 neutral 0.002 (0.99; 0.30) benign
H90Y 1.00 tolerated 0.238 neutral 0.002 (0.99; 0.30) benign
T112A 0.21 tolerated −3.967 deleterious 0.000 (1.00; 0.00) benign
V142I 1.00 tolerated 0.118 neutral 0.000 (1.00; 0.00) benign
A207T 0.00 deleterious −3.543 deleterious 0.999 (0.14; 0.99) damaging
ATP8
L17F 0.29 tolerated −1.984 neutral 0.994 (0.69; 0.97) damaging
M42X −7.636 deleterious
Table 5. Structural classification and pathogenic prediction of mutations in the mtDNA protein-coding 
genes. *Ranges from 0 to 1. The amino acid substitution is predicted damaging if the assigned SIFT score 
is <= 0.05, and the substitution is tolerated if the SIFT score is >0.05. §Variants with a score equal to or 
below−2.5 are considered “deleterious” and variants with a score above −2.5 are considered “neutral”. £The 
conservation of a position in the multi-sequence alignments and the deleterious effect on the protein structure 
results in the Position-Specific Independent Count (PSIC) score that ranges from 0 to 1. The classification 
of the nsSNPs results in Possibly Damaging and Probably Damaging (PSIC > 0.5) or Benign (PSIC < 0.5). 
mtDNA = mitochondrial DNA.
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lymphocytic infiltration with cirrhosis. The mutations were considered pathogenic on the basis of several find-
ings. First, all of the mutations were heteroplasmic, which is associated with deleterious mutations rather than 
neutral polymorphisms. Y95H and S97X were non-synonymous mutations, resulting in truncated ND4 mole-
cules. The other two mutations (T119A and I278V) for ND2 were substitutions of highly conserved nucleotides.
In all BA patients having the mutations described above the clinical and biochemical characteristics of their 
liver functions showed a strong correlation between pathologic changes (cirrhosis) and the frequency of mutant 
mtDNA. It is noteworthy that mtDNA copy number (mtCN) in BA patients was slightly lower than those in the 
Figure 3. Redundancy analysis triplot of 14 BA and 5 CC patients in their genetic variations and relevant 
clinical factors. BA (red circles) and CC (green circles) patients; *, statistically significant predictors of the 
phenotype distribution (anova.cca permutation test, P < 0.1).
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CC patients (Fig. 1a), indicating that BA patients contained to some extent defective mitochondria that affect 
subsequent cell growth and morphology54. In particular, statistical analysis of heteroplasmic sites in mtDNA 
protein-coding genes between BA (i.e., 9, 12, 14, and 17) and CC patients clearly shows that clinical values of 
PT-INR, AST, ALT, and APRI significantly positively correlated with hepatic dysfunction (Fig. 3). Consequently, 
statistical analysis of heteroplasmies clearly support the notion that the parameters of chronic liver injury (i.e., 
METAVIR, PT-INR, APRI, AST, and ALT) positively correleated with the extent of hepatic failure due to critical 
mutations in mtDNA protein-coding genes (i.e., ND2 and ND4) in BA patients (i.e., 8, 9, 12, 14, 16, 17, and 19) 
when compared to CC patients. Recently, it has been reported that skeletal muscle samples exhibit an age-related 
decrease in mtCN, while there was an age-related increase in mtCN for liver samples55. Although heteroplasmies 
at mutational sites in ND2 and ND4 are highly specific for BA, such mutations did not seem to be accumulated 
with aging due to the fact that one BA group (i.e., 9, 12, 14, and 17) with more severe hepatic dysfunction is rela-
tively younger than the other BA group (i.e., 8, 13, 16, and 19) (Table 2).
Mutations in the ND4 protein are very critical for Leber Hereditary Optic Neuropathy; a disorder associated 
with oxidative phosphorylation deficiency56,57. Recent studies suggest that mutated ND2 protein impairs mito-
chondrial complex I assembly, which leads to Leigh syndrome58 and exhibits phenotypes that resemble symptoms 
of mitochondrial disease due to deficient proton pumping activity59. Both ND4 and ND2 subunits of complex 
I are located in proximity to the other mitochondrial subunits in mitochondrial membranes, and ND2 must be 
functional for proton transfer to occur. All of the non-synonymous mutations are located within or close to the 
contact region between intersubunits and are likely to prevent assembly and proton pumping pathway, with loss 
of enzyme activity (Fig. 2). From this perspective, we strongly believe that the mutations found in BA patients are 
unique and pathogenic when compared to mutation sites found in other condition for hepatic dysfunction49–51; 
however, a functional assay remains to be conducted in cultured cells expressing these genetic mutations. The 
high frequency of somatic mutations in the cytochrome b and ATPase 6 coding genes may seem surprising, how-
ever a large number of polymorphisms were observed in the same gene in CC patients (Table 4). Moreover, the 
fact that all pathogenic mutations identified in our BA patients consisted adenine to guanine substitutions further 
speculates that these mutations may result from oxidative damage (Table S3). At this stage, we cannot conclude 
that the mutations in the ND2 and ND4 genes of complex I in our BA patients are definitely somatic. The finding 
of hepatopathy in a patient with BA and no family history of hepatic disorder should alert the clinician to the pos-
sibility of either a ND2 or ND4 gene mutation. Confirmation of the diagnosis requires liver biopsy to investigate 
complex I deficiency and to identify the molecular defect.
Further study to identify the exact mechanism of hepatic mitochondrial damage in chronic liver disease is 
urgently required to understand the progression to the end-stage liver disease. Despite the numerous mitochon-
drial pathways causing mitochondrial diseases, we confined our analysis to mtDNA mutations in the respiratory 
chain. Nevertheless, mtDNA analysis on BA patients using an NGS-based amplicon library sequencing revealed 
that all mtDNA samples derived from 15 mg liver tissues were sequenced deeply enough for accurate SNV detec-
tion with average coverage of over 1000× and the mapped read percentage of over 92%. Thus, we anticipate that 
the amplicon sequencing enables us to identify SNPs in hepatic mtDNAs. Consequently, we found that mutations 
in ND2 and ND4 seem to be highly correlated with hepatic dysfunction particularly in BA patients. This may be 
a promising approach when integrated with current useful bioinformatic tools to establish the mitochondrial 
pathophysiology and biochemical mechanism of hepatic dysfunction in chronic liver disease. In fact, those muta-
tional effects remains challenging because of the complex architecture of the respiratory chain, supramolecular 
arrangement60, and significant cross-talk with nuclear-encoded proteins61. Nevertheless, mtDNA coding region 
variants in this study are suggested as potential genetic risk factors for the generation of cholestasis conditions 
such as BA.
Materials and Methods
Patients characteristics. Nineteen pediatric patients with cholangiopathy (1.9~61.0 week-old children 
with BA and CC) were enrolled at Severance Children’s Hospital (Yonsei University, Seoul, Korea) between 
August, 2011 and July, 2014. This study was approved by Severance Hospital Institutional Review Board (No. 
4-2010-0435), and study protocol was conducted in accordance with the Declaration of Helsinki. Patients were 
enrolled in this study after written informed consent including the use of liver tissue was obtained from each 
patient. As a control group, the CC group was defined as children that exhibited no abnormal liver function, 
showed normal liver histology and only had a cystic dilatation of bile duct. For all pediatric patients, the demo-
graphic and biochemical parameters such as sex, age in weeks, serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin (T.Bil), direct bilirubin (D.Bil), protein, albumin, and gamma glutamyl 
transpeptidase (γ-GT), were included at the time of liver wedge biopsy during surgery.
Collection and qualification of liver tissue. Liver wedge biopsy specimens were collected from the 
patients at surgery (Kasai hepatoportoenterostomy or liver transplantation in BA group, choledochojejunostomy 
with a Roux-en-Y anastomosis of dilated bile duct in CC group). All liver tissues were immediately frozen in 
liquid nitrogen and stored at −70 °C until used. For qualification of liver tissues of BA as a disease group and 
CC as a control group, liver fibrosis and necroinflammatory activity of each group were examined according to 
the METAVIR scoring system62. The METAVIR scoring system consists of five stages, based on the architectural 
features of portal fibrosis: F0 = normal, F1 = portal fibrosis without septa, F2 = portal fibrosis and few septa, 
F3 = numerous septa without cirrhosis, and F4 = cirrhosis63,64.
Liver tissue mitochondria and mtDNA extraction. Mitochondria were isolated from liver tissue sam-
ples of 14 BA patients and five CC patients using a mitochondrial isolation kit for tissue (Thermo Scientific, 
Rockford, IL). For the purpose of this analysis, option A (Isolation of Mitochondria from Soft Tissues) from 
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the manufacturer’s protocol 1: Reagent-based Method for Soft Tissues was used. Briefly, each liver tissue (11 ~ 
80 mg) resuspended in 800 µL PBS were initially disrupted and homogenized using a pre-chilled 2 ml glass dounce 
(Wheaton, Millville, NY) to purify mitochondria.
Mitochondrial DNAs (mtDNAs) were extracted from the isolated mitochondrial samples using a QIAamp 
DNA Mini Kit (Quiagen, Valencia, CA) as per option ‘Isolation of genomic DNA from bacterial cultures’. The 
extracted mitochondrial DNAs were quantified by Qubit 2.0 fluorometer using a Qubit dsDNA HS assay Kit (Life 
Technologies, Carlsbad, CA) and qualified by 1% agarose gel electrophoresis.
Determination of mtDNA Copy Number. Total DNA was extracted from liver samples. The mtDNA copy 
numbers were measured by real-time PCR using a modified method of Tiao et al.65, as previously described66. 
The PCR primers complementary to nuclear β-actin gene were 5′-GAAATCGTGCGTGACATTAAAG-3′ and 
5′-ATCGGAACCGCTCATTG-3′. The primers to detect mtDNA were complementary to the mitochondrial COX1 
gene, which were 5′-TTCGCCGACCGTTGACTATTCTCT-3′ and 5′-AAGATTATTACAAATGCATGGGC-3′. 
PCR was performed in a BioRad CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA) using the iQ 
SYBR Green Supermix kit. DNA (10 pg) was mixed with 10 μl of SYBR Green mix containing 10 nmol of primers, 
in a final volume of 20 μl. The PCR conditions were as follows: initial 50 °C for 2 min, 95 °C for 1 min, 40 cycles 
of denaturation at 95 °C for 15 s, annealing at 60 °C for 20 s, and primer extension at 72 °C for 15 s. The thresh-
old cycle number (Ct) values of the β-actin gene and the mitochondrial COX1 gene were determined for each 
individual quantitative PCR run. Ct value differences were used to quantify mtDNA copy number relative to the 
β-actin gene according to the following equation: the relative copy number (Rc) = 2 ΔCt, where ΔCt is Ctβ-actin  
− CtmtDNA66. Each measurement was performed at least 3 times and was normalized against a serial dilution of a 
control DNA sample.
Sequencing library construction. Two types of sequencing libraries were prepared as described below. 
Briefly, direct sequencing library was prepared using total extracted mtDNAs and the mtDNA amplicon library 
was made by PCR with amplified fragments of mitochondrial DNAs to avoid the nuclear DNA (nDNA) contam-
ination in subsequent making library. For the mtDNA amplicon library, the entire mtDNA was initially amplified 
as four fragments by PCR using a set of primers specific for mitochondrial origin co-amplification to prevent 
nDNA sequences60. As shown in Fig. 1b, mtDNA fragments 1 to 4 were amplified from mtDNA using the prim-
ers 14898 F (5′-TAGCCATGCACTACTCACCAGA-3′) and 1677R (5′-GTTTAGCTCAGAGCGGTCAAGT-3′), 
1404 F (5′-ACTTAAGGGTCGAAGGTGGATT-3′) and 6739 R (5′-GATATCATAGCTCAGACCATACC-3′), 
6511 F (5′-CTGCTGGCATCACTATACTACTA-3′) and 10648 R (5′-GGCACAATATTGGCTAAGAGGG-3′), and 
10360 F (5′-GTCTGGCCTATGAGTGACTACA-3′) and 15349 R (5′-GTGCAAGAATAGGAGGTGGAGT-3′), 
respectively. The PCR mixture (50 μl) contained 2.5 mM MgCl2, 20 ng of mtDNA, 10 pmol of each primer, 0.2 mM 
dNTP mix, and 1.25 U of PrimeSTAR HS DNA polymerase (Takara Bio, Ohtsu, Japan). After the initial denatur-
ation for 2 min at 95 °C, the DNA was amplified during 30 cycles of 20 sec denaturation at 95 °C, 40 sec annealing 
at 57 °C and 5 min extension at 72 °C; this was followed by a final extension step of 5 min at 72 °C. The size of PCR 
products were confirmed by 1% agarose gel electrophoresis, purified further using an AMPure kit (Beckman 
Coulter, Brea, CA) and pooled in equimolar amounts to generate fragment-sequencing libraries. For the 200 bp 
libraries, 30~300 ng mtDNA or entire amplified DNA was sheared by Bioruptor Sonication system (Diagenode, 
Denville, NJ). The rest of steps in the library preparation were performed using the Ion Plus Fragment Library 
Kit and the Ion DNA Barcoding 1–16 Kit (Life Technologies, Gaithersburg, MD) according to the manufacturer’s 
instructions. After the sheared DNA end-repair and adapter ligation steps, the library was made from mtDNA 
size-selected using a 2% E-Gel SizeSelect (Invitrogen, Carlsbad, CA) instrument, followed by 8 cycles of final 
PCR amplification. The quantification and size distribution of each library was performed by Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA).
Sequencing on an ion torrent platform. For the clonal amplified sequencing templates, the libraries were 
pooled in equimolar amounts and emulsion PCR on Ion OneTouch system with Ion OneTouch 200 Template kit 
v2 (Life Technologies, Gaithersburg, MD). The templates were automatically enriched with the Ion OneTouch ES 
system (Life Technologies). Next Generation Sequencing was performed using the Ion Torrent Personal Genome 
Machine (PGM) sequencer system using a 316D sequencing chip (Life Technologies)67. Raw sequence data were 
analyzed by Ion Torrent Suite v4.0.2.
Sequence analysis of the mitochondrial genome. Homo sapiens mitochondrial complete genome 
(NC_012920.1) was used as the reference sequence. FASTQ format sequence files were applied to sequence read 
mapping and variant calling by using the “map read to reference” tool and a “quality-based variant detection” tool 
in the CLC genomics workbench v7.0.3 software (CLC-bio, Aarhus, Denmark). The “Map read to reference” tool 
was used with default parameters applying bioinformatic costs for mismatches of “2”, indel costs of “3”, length 
fraction of “0.5”, similarity fraction of “0.8” was performed. Quality-based variant detection with default param-
eters neighborhood radius of “5”, maximum gap and mismatch count of “2”, minimum neighborhood quality 
of “15”, minimum central quality of “20”, minimum coverage of “10”, minimum variant frequency (%) of “35”, 
variant filter of “Ion homopolymer indels” and genetic code “2 vertebrate mitochondrial”. The mitochondrial 
DNA haplogroups and mutations in encoding regions were determined by using MITOMAP68 and MitoTool69.
Structural mapping and analysis. Thirty-four mutation sites in mtDNA protein coding genes 
were mapped onto their corresponding human model structures. For human complexes I to V models, the 
SWISS-MODEL server was used with available high-resolution structures of the human, bovine, ovine and 
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bacterial enzymes (PDB accession codes, 4HEA (for subunits ND1, ND2, ND4L, and ND6), 5XTC (ND3), 5LNK 
(ND5), 1LOL (Cyt b), 3ABM (COX1, COX2, and COX3), and 5ARA (ATP6)) as template structures.
For mutational effect on the structure and function of the respiratory chain complexes, predictive approaches 
for amino acid substitutions (AAS) analysis were performed using SIFT (http://sift.jcvi.org), PROVEAN (http://
provean.jcvi.org), and Polyphen-2 (http://genetics.bwh.harvard.edu/pph/) web servers.
Multivariate statistical analysis. The redundancy analysis (RDA) was done by using the rda function in 
the vegan library of the R software version 3.4.1 (www.r-project.org)70,71. Instead of relative abundance data, we 
used measures of heteroplasmic sites including SNPs and InDels, and the histological and clinical criteria in our 
analysis is defined by phenotype variables. The statistical significance of phenotype variables was assessed with 
the function anova.cca in vegan package, using 999 permutations to test for the marginal significance of each term 
after accounting for the effects of the others. The permutation method was implemented to assess whether certain 
genomic regions (functional genes) were enriched for phenotype-associated variations by calculating empirical 
P-values of the phenotypes variables with respect to variantation matrix.
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